Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prevnar full dose schedule restored

Executive Summary

The Centers for Disease Control & Prevention reinstates full four-dose schedule for Wyeth's pneumococcal conjugate vaccine Prevnar Sept. 16. CDC recommended deferring the third and fourth doses because of supply problems; it reinstated the third dose recommendation in July (1"The Pink Sheet" July 12, 2004, In Brief). Wyeth CEO Robert Essner told the Bear Stearns health care conference Sept. 14 that Prevnar's supply issues were "under good control"...

You may also be interested in...

No News Is Good News For Wyeth: Smooth Quarter Will Beat Expectations

A lack of "negative surprises" for Wyeth during the first quarter is contributing to financial results well above analyst estimates, the company said

CDC recommends reinstating third Prevnar dose

Health care providers should reinstate administration of third dose of Wyeth's pneumococcal conjugate vaccinePrevnar for healthy children under two years old, Centers for Disease Control & Prevention says July 8. CDC recommended suspending the third and fourth doses of Prevnar in March due to a "markedly worse" than anticipated production shortfall in Wyeth's vial-filling process (1"The Pink Sheet" March 8, 2004, p. 25). CDC expects that Prevnar supply will be adequate for four-dose coverage in the fall (2"The Pink Sheet" June 7, 2004, p.30)...

Amwell Stock Rises 28% In Market Debut

Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts